t(8;21)(q22;q22) results in the AML1-ETO (A1E) fusion gene and is a common cytogenetic abnormality in acute myeloid leukemia (AML). Although insertions at the breakpoint region of the A1E fusion transcripts have been reported, additional structural alterations are largely uncharacterized. By RT-PCR amplifications and DNA sequencing, numerous in-frame and out-of-frame AML1b-ETO and AML1c-ETO transcripts were identified in 13 pediatric t(8;21) AMLs, likely resulting from alternate splicing, internal deletions and/or breakpoint region insertions involving both the AML1 (RUNX1) and ETO regions. The in-frame A1E fusion transcript forms represented minor forms. These structure alterations were found in AML1c-ETO but not AML1b-ETO transcripts in two adult t(8;21) AMLs. Although no analogous alterations were detected in native AML1b transcripts, identical alterations in native ETO transcripts were identified. When transfected into HeLa cells, only AML1b, and not the in-frame A1E forms, transactivated the GM-CSF promoter. In co-transfection experiments, the effects of A1E proteins on GM-CSF transactivation by AML1b ranged from repressive to activating. Our results demonstrate a remarkable and unprecedented heterogeneity in A1E fusion transcripts in t(8;21) myeloblasts and suggest that synthesis of alternate A1E transcript and protein forms can significantly impact the regulation of AML1 responsive genes.
Introduction t(8;21)(q22;q22) is one of the most common cytogenetic abnormalities in acute myeloid leukemia (AML), occurring in 7-8% of adult and B12% of childhood cases (Raimondi et al., 1999; Strout et al., 1999; Marcucci et al., 2000) . t(8;21)(q22;q22) is a balanced translocation between chromosomes 8 and 21, resulting in fusion of the AML1 (RUNX1) gene located on chromosome 21 with the ETO (MTG8) gene located on chromosome 8 (Erickson et al., 1992; Nucifora et al., 1993) . Adult patients with t(8;21) AML have been reported to have higher complete remission rates after standard induction therapy and favorable outcomes, especially after dose-intensified ara-C (cytosine arabinoside)-based post-remission therapy (Bloomfield et al., 1998; Grimwade et al., 1998; Byrd et al., 1999; Schlenk et al., 2004) . However, reports on children with t(8;21) AML have been mixed and include both favorable as well as standard prognoses (Grimwade et al., 1998; Chang et al., 2000; Rubnitz et al., 2002; Entz-Werle et al., 2005; Kardos et al., 2005; Perel et al., 2005; Smith et al., 2005) . Recent studies using real-time reverse transcription (RT)-PCR quantitation of AML1-ETO (A1E) fusion transcripts in primary t(8;21) AML samples identified an association between high A1E transcript levels at diagnosis and shorter event-free survivals or overall survivals (Schnittger et al., 2003; Leroy et al., 2005; Yoo et al., 2005) , suggesting that expression of A1E fusion proteins contribute to resistance to chemotherapy drugs such as ara-C. However, when the wild-type A1E fusion protein was inducibly overexpressed in U937 AML cells, it resulted in increased basal and drug-induced apoptosis (Lu et al., 2006) . These results make a compelling argument that further investigation of the structural and functional features of A1E fusion transcripts and proteins in t(8;21) pediatric AMLs is warranted.
The AML1 gene encodes a DNA-binding protein that regulates hematopoietic gene expression (Michaud et al., 2003; Peterson and Zhang, 2004) and has the potential to encode multiple transcript and protein isoforms (termed AML1a, AML1b and AML1c), due to differential use of promoters (distal P1 and proximal P2, respectively) and alternate splicing of upstream exons (Miyoshi et al., 1995) . AML1a and AML1b transcripts are both transcribed from the P2 promoter and encode identical N-terminal regions; however, AML1a lacks the C-terminal transactivation domain present in AML1b. AML1c is transcribed from the P1 promoter and encodes a distinct N-terminal region from AML1a/1b, whereas its C terminus is identical to that of AML1b (Miyoshi et al., 1995) . All three forms include a central domain termed the runt homology domain (RHD), which is critical for both DNA binding and heterodimerization for all AML1 proteins (Lutterbach and Hiebert, 2000) .
t(8;21) has been reported to result in the synthesis of A1E transcripts exclusively from the proximal P2 promoter analogous to AML1a/1b (Peterson and Zhang, 2004) , and generation of A1E fusion protein(s). The breakpoints within the AML1 locus can vary, although they reportedly cluster in intron 5 with three BCRs (breakpoint cluster regions). For ETO, the break points are clustered in two introns, with one BCR in intron 1a and three BCRs in intron 1b (Peterson and Zhang, 2004) . Previously, five distinct A1E fusion transcript forms (designated I to V) were identified, which differed in their break points (Saunders et al., 1996) . Of these, only type I was believed to include AML1 sequence (as AML1a/b, transcribed from the P2 promoter) 'in-frame' with ETO, resulting in functionally active fusion protein.
Conversely, A1E forms II through V were 'out-offrame' and, thus, would encode truncated proteins or forms otherwise unrecognizable as A1E. However, the biological and clinical significance of these assorted A1E transcript forms was not assessed. Recently, Yan et al. (2004 Yan et al. ( , 2006 reported that the loss of the C-terminal NCoR/SMRT-interacting domain of A1E resulting from alternate use of exon 9a of ETO transforms A1E into a potent leukemogenic protein.
In this report, we further explore the expression, structure and function of A1E transcripts and proteins. By PCR amplification and sequencing of the full-length A1E complementary DNAs (cDNAs) prepared from 13 pediatric and 2 adult t(8;21) AML samples, we made two unexpected findings. (i) Both AML1a/b-ETO (hereafter called A1bE) and AML1c-ETO (A1cE) fusion transcript forms were identified. Further, (ii) an unprecedented heterogeneity in A1bE and A1cE fusion transcripts was detected, involving both in-frame and out-of-frame forms, likely due to alternate splicing and/or internal deletions/ insertions. Although alternate forms of A1E have been described (Saunders et al., 1996) , the present report significantly extends these results in terms of the variety of these forms and their functional significance in t(8;21) AML.
Results
Characterization of A1E fusion transcripts and promoter usage in t(8;21) myeloblasts Three AML1 isoforms were previously described (AML1a, AML1b and AML1c), resulting from alternate promoter/non-coding exon usage and splicing (Miyoshi et al., 1995) . Although A1E fusion transcripts were originally believed to include only 5 0 sequence identical to that in AML1a/1b transcripts and be transcribed from the proximal P2 promoter, it seemed likely that A1E transcripts were transcribed from both P1 and P2 AML1 promoters (as A1cE and A1bE transcripts, respectively) ( Figure 1a ). The alternate exon 9a (155 bp) identified in ETO (Wolford and Prochazka, 1998) could also be present in the A1E transcripts (Yan et al., 2006) . To assess these possibilities, we characterized full-length A1bE and A1cE transcripts in 13 pediatric and 2 adult t(8;21) AMLs, the t(8;21) AML cell line, Kasumi-1, and a t(8;21)-negative AML cell line, CMK, by RT-PCR using upstream AML1b/AML1c-specific primers (located in the AML1 5 0 -untranslated regions; UTRs) and a downstream ETO primer (located in the ETO 3 0 -UTR) (Figures 1b and c) . Heterogeneous PCR products were reproducibly detected for the pediatric samples for both primer sets and with cDNAs prepared with oligo-dT. Although similar results were obtained for adult t(8;21) AMLs for A1cE, for A1bE only a single band was detected.
By automated sequencing of up to 20 bacterial clones for each patient specimen, we identified 9 in-frame A1bE transcripts (2 of which contained ETO exon 9a; Figure 2a and Table 1 ) and 5 in-frame A1cE transcripts (2 with ETO exon 9a, Figure 2b and Table 1) , along with multiple out-of-frame A1bE and A1cE forms (Supplementary Tables S2 and S3 ). On the basis of frequencies of the individual clones by direct sequencing, the inframe A1bE and A1cE fusion transcripts represented minor transcript forms in the 13 pediatric t(8;21) AML samples (Table 1) . Although similar results were obtained for A1cE in adult samples, full-length A1bEWT was the only fusion transcript form detected in the two adult patient samples. The most frequent inframe A1bE fusion transcript form in the pediatric t(8;21) AMLs was A1bE#3, which contained a 156-bp deletion in exon 3 (including a portion of the RHD) of AML1. A1bE#3 was present in 12 out of 13 pediatric patient samples and in Kasumi-1 cells, with frequencies estimated at 5.3-93.3% of total A1bE. In contrast to the two adult samples, full-length (2.2 kb) A1bE was only detected in 4 out of 13 pediatric patients, with frequencies ranging from 13.3 to 64.7% of total A1bE. None of the full-length A1cE (B2.3 kb) was detected in either the pediatric or adult samples. Rather, a range of deleted forms was detected with no significant difference between the pediatric and adult samples (Table 1 and Figure 2) . Analogous results were obtained by real-time RT-PCR. In these experiments, total in-frame A1E transcript forms ranged from 1 to 25% of total A1E transcripts in all the 13 pediatric and 2 adult t(8;21) AML patient samples and in the t(8;21) AML cell line Kasumi-1 (Figure 3 , lower panel). These results further confirm that the in-frame A1E transcript forms are minor forms in t(8;21) AML.
These results indicate that both the P1 and P2 AML1 promoters can transcribe A1E fusion transcripts. They also document an unprecedented level of A1E transcript heterogeneity involving multiple promoters, internal deletions and possibly alternative splicing, including exons 2-5 of the AML1 gene and exons 2, 3 and 9a of the ETO gene. For the 13 t(8;21) pediatric patients, there was no association between either total A1E or total inframe A1E fusion transcripts and clinical outcomes (data not shown).
Characterization of 'native' AML1b and ETO transcripts in t(8;21) myeloblasts The structural alterations detected in A1E fusion transcripts may also occur in 'native' AML1 or ETO transcripts. To test this, full-length native AML1b transcripts were PCR amplified in cDNAs from the 13 pediatric and 2 adult t(8;21) AML patient samples, the Kasumi-1 and CMK cells using an upstream primer in the 5 0 -UTR and a downstream primer in the 3 0 -UTR (the latter region is deleted in the A1E transcripts). Multiple transcripts were detected in each patient sample, except for sample A225 for which no transcripts were detected, and in Kasumi-1 cells (Figure 4a ). Upon cloning and DNA sequencing the amplicons from (a) A schematic representation of genomic structure of the A1E fusion gene and mRNA structures of the two types of A1E fusion transcripts (A1bE and A1cE), transcribed from the proximal and distal promoters, respectively, is shown. In addition, each transcript form is shown with the alternately spliced exon 9a of ETO. The light green boxes represent exons of AML1, whereas the blue boxes represent exons of ETO. The red box upstream of exon 1 of AML1 represents the 5 0 -UTR of AML1c, whereas the black box upstream of exon 3 of AML1 represents the 5 0 -UTR of AML1b. The full-length A1bE (b) and A1cE (c) fusion transcripts were PCR amplified with upstream AML1b or AML1c primers and downstream ETO-specific primers. The amplicons were separated on a 1.5% agarose gel and visualized by ethidium bromide staining. The locations of the AML1b, AML1c and ETO primers are indicated by arrows, and the RHD is also noted on the schematics of both A1bE (b) and A1cE (c). A1bE, AML1b-ETO; A1cE, AML1c-ETO; AML, acute myeloid leukemia; RHD, Runt homology domain; UTR, untranslated region.
representative samples, we identified (i) wild-type AML1b, (ii) the previously reported AML1b missing exon 6 (Miyoshi et al., 1995) and (iii) AML1b missing exon 6 and containing a 99-bp deletion in exon 8. Importantly, no structural alterations analogous to those found in the A1E fusion transcripts were detected in exons 3-5 of AML1b.
To amplify native ETO transcripts, PCRs were performed with an upstream primer located in the 5 0 -UTR (this region is deleted in the A1E fusion transcripts) and a downstream reverse primer located in exon 4. In both t(8;21) AML patient samples and Kasumi-1 cells, two major amplicons (518 and 276 bp) were detected ( Figure 4b , upper panel), corresponding to unmodified ETO and ETO missing exon 3. The latter form was not detected in the CMK cells. To determine whether exon 9a is present in native ETO, PCRs were performed with the same upstream primer and a downstream primer located in exon 9a. As shown in Figure 4b (lower panel), exon 9a was detected in up to 6 out of 13 pediatric samples and 1 out of 2 adult patient samples.
Thus, the AML1 sequence alterations in the A1E transcripts appear to be unique to the fusion gene. Conversely, identical patterns of alternate splicing of exon 3 and use of exon 9a occurred in both native ETO and the A1E fusion transcripts.
Functional role of the novel in-frame A1E fusion proteins To assess the functional roles of the novel in-frame A1E transcripts, cDNAs for these forms (in pcDNA3) were co-transfected with a promoter reporter construct for granulocyte-macrophage colony-stimulating factor (GM-CSF; a known AML1 target gene) (Michaud et al., 2003) into HeLa cells. Extracts were prepared and cellular A1E proteins were assayed on western blots and promoter activity measured by luciferase assays.
On western blots probed with AML1 or ETO antibodies, AML1a, AML1b, ETO, A1bE and A1cE proteins were detected in the transfected cells (Figure 5a ), although these frequently migrated as multiple bands, likely due to posttranslational modifications (Erickson et al., 1996) . The AML1 antibody (3D9, epitope in the RHD of AML1) detected A1bEWT, A1bE#2-5, and the truncated A1bEWT-9a and A1bE#3-9a forms near their expected molecular masses ( Figure 5a , lower left panel; Table 1 ). Neither of the remaining A1bE forms nor any of the A1cE forms were detected due to partial or entire deletions of the RHD (Figure 2 ). ETO antibody (C-20, epitope located in the C terminus of ETO) identified major bands at the expected molecular masses of B50-90 kDa for all of the A1E proteins ( Figure 5a upper left panel; Table 1 ), except for A1bEWT-9a and A1bE#3-9a ( Figure 5 ), and A1cE#2-9a and A1cE#3-9a (not shown) (reflecting the loss of the C-terminal region of ETO).
Surprisingly, the ectopically expressed A1bEWT and A1bE#3 proteins from HeLa cells both migrated faster than the major endogenous Kasumi-1 A1E protein (identified as A1bE#3; noted with an arrow in Figure 5a , right-hand panels). This suggests that posttranslational modifications of A1E proteins in Kasumi-1 and HeLa cells are different. The two faster migrating protein forms in Kasumi-1 cells (indicated with a box) were only detected with ETO antibody and could be the A1cE#1 and A1cE#2 proteins (see Table 1 ).
Interestingly, with the ETO C-20 antibody, an additional series of bands (B60-70 kDa) identical to those in ETO transfections was detected in transfections with the A1bEWT, A1bE#2-5 and A1cE#1-3 constructs ( Figure 5a upper left panel; labeled 'ETO'). Because no analogous banding was detected with AML1 antibody, a likely possibility is that these represent ETO proteins (including posttranslationally modified forms) translated from a downstream translation initiation site in exon 2 (position 24 relative to the first nucleotide of exon 2) of the ETO gene. To further investigate this interesting possibility, a representative A1bE out-offrame form (3(À156).4.5-( þ 82)-2.3.4//11, Supplementary Table S2 ), which preserved intact ETO sequence was transfected into HeLa cells. When probed with the ETO antibody, the ETO-like bands were again detected (lane designated A1bE o-o-f, Figure 5b , upper panel). These same bands were not detected when the same blot was stripped and reprobed by AML1 antibody. Collectively, these results strongly suggest that some of the A1E fusion transcript forms (both in-frame and out-offrame) can translate ETO protein.
Transfectants for which immunoreactive proteins were detected by either AML1 or ETO antibodies were assayed with luciferase reporters. In these experiments, AML1b dramatically stimulated GM-CSF promoter activity (approximately eightfold) above basal levels ( Figure 5c ). Conversely, AML1a, ETO and the remainder of the A1E deletion isoforms were effectively inert. When added together with the AML1b construct, AML1a and A1bEWT, A1bE#2, A1bE#3, A1bEWT-9a, and A1bE#3-9a significantly but variably decreased GM-CSF promoter transactivation by AML1b (B20-66%; Figure 5d ). Interestingly, there was an inverse association between the size of AML1 exon 3 deletion (particularly apparent for the series of progressively deleted constructs, A1bEWT, A1bE#2, A1bE#3 and A1bE#5; A1bE#4 is not included because this form contains a 72-bp insertion) and loss of GM-CSF transactivation by AML1b. In contrast, A1cE#2 significantly increased AML1b transactivation (Btwo-fold over AML1b, alone). ETO and the remainder of the A1E fusion proteins had only minor and statistically insignificant effects on AML1b transactivation. Thus, the previously reported A1bEWT and A1bEWT-9a forms along with the novel A1bE#2, A1bE#3, A1bE#3-9a and A1cE#2 fusion proteins identified in this study appear to modulate the extent of GM-CSF promoter transactivation by AML1b. Discussion t(8;21)(q22;q22) is one of the most common cytogenetic abnormalities in AML and exhibits considerable heterogeneity in its accompanying clinical and immunophenotypic features. Reports that t(8;21) can be a favorable prognostic factor in at least some AML clinical trials (Grimwade et al., 1998) suggest that generation of the A1E fusion gene somehow contributes to clinical heterogeneity of the disease and also influences chemotherapy responses of this unique group of patients. However, neither the extent nor the mechanism by which these alterations affect chemotherapy sensitivity is established, although A1E has been shown to act as a transcription repressor of a number of genes including MDR1 (Lutterbach et al., 1998) and as an activator of Bcl-2 (Klampfer et al., 1996) .
By amplifying the full-length A1bE and A1cE transcripts in 13 primary pediatric t(8;21) AML samples and Kasumi-1 cells, multiple in-frame and out-of-frame forms were identified involving both the AML1 and ETO regions. For AML1, exons 2-5 were variously deleted, whereas deletions of exons 2 and 3 of ETO were also detected, along with alternate usage of exon 9a. These structural alterations could profoundly impact fusion protein binding to DNA and/or alter associations with HDACs and NCoR/SMRT complexes. The AML1 sequence alterations were A1E fusion gene-specific, as analogous structural changes were not found in The frequency for each A1E fusion transcript represents the frequency within individual patient samples (a range in frequency indicates multiple patient samples) and was determined by the ratio of positive clones to the total number of clones sequenced (typically 20) for either A1bE or A1cE, including both in-frame and out-of-frame forms.
e Indicates the patient samples in which each fusion transcript form was detected.
Novel AML1-ETO fusion transcripts in t(8;21) AML KM LaFiura et al transcripts derived from the native AML1 gene. However, an analogous skipping of exon 3 and inclusion of exon 9a were detected in native ETO transcripts. DNA sequencing results suggested that the out-of-frame A1E forms represented the majority of fusion transcripts, which was directly confirmed by real-time PCR analysis. Of the in-frame A1bE transcripts, there was a low level of the full-length form (none in the Kasumi-1 cells) and A1bE#3 was most frequently detected. Interestingly, with the two adult samples, only full-length in-frame A1bE was detected. For A1cE transcripts, none of the full-length form was detected and the forms and distribution between adults and children were similar. Although out-of-frame A1E forms (resulting from variable break points) have been reported (Saunders et al., 1996) , neither the extent of transcript heterogeneity reported here nor the existence of most of these alternate in-frame forms was previously described. Possible differences in A1E forms between adult and pediatric t(8;21) AMLs will be the topic of future studies.
To determine the function of the novel in-frame A1bE and A1cE transcripts identified in primary t(8;21) AML samples, complete cDNAs for these forms were cotransfected into HeLa cells, along with a promoter reporter construct for GM-CSF, a known AML1 target gene (Michaud et al., 2003) . Unlike AML1b, the A1E fusion proteins had no significant transactivating effects on the GM-CSF promoter, consistent with previously reported results (Frank et al., 1995) . When added together with the AML1b construct, the A1bE forms which contained the majority of the RHD, including WT, #2, #3, WT-9a and #3-9a, repressed AML1b transactivation of the GM-CSF promoter, such that the magnitude of repression was inversely proportional to the size of the deletion in the RHD. Interestingly, insertion of exon 9a, resulting in deletion of the ETO C terminus in A1bEWT-9a and A1bE#3-9a, had no effect on this repressive effect. With the lone exception of A1cE#2, the rest of the A1E fusion proteins were completely inert toward GM-CSF transactivation by AML1b, most likely due to the loss of the RHD. The basis for the anomalous result with A1cE#2 is presently unknown and is under investigation. In any case, our data strongly suggest that DNA binding through the RHD is likely to be critical for the repressive effects of the A1bE fusion proteins and raise the interesting possibility that the presence of alternate in-frame A1E proteins can effectively and variably modulate transcription of AML1 target genes. A modest inhibition by AML1a (missing the C-terminal transcriptional activa- Kasumi-1  A27  A35  A58  A60  A104  A207  A215  A216  A220  A223  A225  A227  A236  A254 A1Etotal/F A1Etotal/R …… …… Figure 3 Real-time reverse transcription (RT)-PCR quantitation of total A1E and total in-frame A1E transcripts in t(8;21) AML patients. Total A1E transcripts and total in-frame A1E transcripts were quantitated in the 13 pediatric and 2 adult t(8;21) AML patient samples using total A1E and total in-frame A1E-specific primers (indicated by arrows on the schematics shown in the upper panel) and normalized to GAPDH (glyceraldehyde 3-phosphate dehydrogenase) transcripts. Data are presented as mean ± range from two independent experiments. These results further confirm that the in-frame A1E fusion transcript forms are minor forms in t(8;21) AML. AML, acute myeloid leukemia. tion domain) was also detected, likely due to direct competition with AML1b for DNA binding (Tanaka et al., 1995) , analogous to the more potent effect of A1bEWT-#3 on GM-CSF transactivation. On western blots of cellular proteins from transfected HeLa cells, A1bE and A1cE fusion proteins were detected by ETO antibody. Surprisingly, a series of bands was also identified that co-migrated with ETO proteins in transfections with the A1bEWT, A1bE#2 through A1bE#5, and A1cE#1 through A1cE#3. We suggest that these bands must represent bona fide ETO protein initiated downstream from an AUG in exon 2 into the ETO portion of the fusion transcripts. This interpretation is strongly supported by our finding that an out-of-frame A1bE fusion transcript form that includes intact ETO sequence can also translate identical ETO species. Thus, our results argue that ETO protein levels and/or function can be largely preserved in spite of a disruption of the ETO gene locus and the formation of the A1E fusion gene, and suggest yet another component in the complex interplay among AML1, ETO and A1E fusion proteins in t(8;21) myeloblasts.
In conclusion, the results of the present study demonstrate an unprecedented level of transcript 
Cell culture
The human HeLa cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). The AML cell line, CMK and the t(8;21) AML cell line, Kasumi-1, were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). All cell lines were cultured in RPMI 1640 with 10% fetal bovine serum and 2 mM L-glutamine plus 100 U/ml penicillin and 100 mg/ml streptomycin at 37 1C.
Characterization of A1E fusion transcripts, native AML1b and ETO transcripts in t(8;21) myeloblasts To characterize A1E fusion transcripts and native AML1b and ETO transcripts in the t(8;21)-positive AML patient samples, the t(8;21) AML cell line, Kasumi-1, and a t(8;21)-negative AML cell line, CMK, cDNAs were prepared from 1 mg of total RNAs, using Oligo-dT and SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). For the A1E transcripts, cDNAs were PCR amplified with upstream AML1b-and AM1c-specific primers (A1bE/F1552, 5 0 -GGGT CCTAACTCAATCGGCTTGTTGT-3 0 ; AML1c/F, 5 0 -AGC GATGGCTTCAGACAGCATATTTGAG-3 0 ), both located in their respective 5 0 -UTRs, and a downstream ETO reverse primer (A1E/R3863, 5 0 -GGTTTCGCGTTGGTTGTGTTGT CTTGGT-3 0 , located in the 3 0 -UTR). To amplify the native AML1b full-length transcripts, an upstream primer (AML1a/ F1562-KpnI, 5 0 -TTCACGGTACCTCAATCGGCTTGTTGT GATGCGTAT-3 0 ) located in the 5 0 -UTR, and a downstream primer (AML1c/R-XhoI, 5 0 -TTCACCTCGAGGCCTGACC TACAGCGAGATCCTGG-3 0 ) located in the 3 0 -UTR were used. To amplify native ETO transcripts, an upstream primer (ETO/F214, 5 0 -CCACTTGAAAAACTGAGGTGCTT-3 0 ) located in the 5 0 -UTR, and downstream ETO reverse primers (A1E/R1043, 5 0 -ATGACAAAAGGTCTCAGTGGGAAGT TAGTAGC-3 0 , located in exon 4 of ETO, and A1Ea-2/ R1761, 5 0 -CTCAAAGCTGGGCAGCACCTAGGTAT-3 0 , located in exon 9a of ETO) were used. All amplifications used a high-fidelity polymerase (Easy A; Stratagene, La Jolla, CA, USA) and an initial denaturation at 95 1C for 4 min, 35-40 cycles of 30 s at 95 1C, 30 s at 60-65 1C and 1 min at 72 1C, followed by a 7-min elongation at 72 1C. Amplicons were resolved on a 1.5% agarose gel to visualize the products, and were cloned either directly from the PCR reaction mix or from gel-purified products into pCRIITOPO vector (Invitrogen). Plasmid DNAs from 20 clones for each patient sample were prepared for automated DNA sequencing at the Genetics/ Genomics Core Facility of Wayne State University. Sequence comparisons and translation analyses were performed using programs available from the National Center for Biotechnology Information (NCBI).
Quantification of total A1E and total in-frame A1E transcripts in t(8;21) AMLs by real-time RT-PCR Complementary DNAs from above were purified with the QIAquick PCR Purification Kit (Qiagen). To quantitate total A1E transcripts and total in-frame A1E fusion transcripts in the t(8;21) AML samples, real-time RT-PCR assays were performed using an upstream AML1 and downstream ETO primers (forward: 5 0 -CCACCTACCACAGAGCCATCA-3 0 (A1Etotal/F, located in exon 5 of AML1) and reverse: 5 0 -GGAGTCAGCCTAGATTGCGTCTTC-3 0 (A1Etotal/R, located in exon 2 of ETO) for total A1E; forward: 5 0 -GAACCTCGAAATCGTCCTGA-3 0 (flanking the type I break point) and reverse: 5 0 -GAAGGCCCATTGCTGA-3 0 (located in exon 3 of ETO) for total in-frame A1E), with SYBR Green detection on a LightCycler real-time PCR machine (Roche, Indianapolis, IN, USA) (Ge et al., 2005) . External standard curves for the total A1E and total in-frame A1E fusion gene were constructed using serial dilutions of a linear standard, prepared by cloning amplicons from Kasumi-1 cells into pGEM-T-Easy plasmid (Promega, Madison, WI, USA) and digesting with NcoI. The specificity of the amplicons from primary AMLs was confirmed by melting curve analysis and DNA sequencing. The levels of A1E fusion transcripts were normalized to levels of GAPDH transcripts.
Construction of promoter and expression constructs, transient transfections and luciferase assays
The GM-CSF promoter was PCR amplified from genomic DNA prepared from CMK cells using forward (GM-CSFPro/ F-NheI, 5 0 -TTCACGCTAGCGCTCCTGG TGTCTTCTGG GGGCTAC-3 0 ) and reverse (GM-CSFPro/R-XhoI, 5 0 -TTCA CCTCGAG TCTGTGTACTGGGCTCACTGGCAAAA-3 0 ) primers (primers included restriction sites for NheI and XhoI (underlined), respectively). The amplicons were digested with NheI and XhoI, and were cloned into NheI/XhoI sites of the pGL3Basic reporter vector to generate pGL3B-GM-CSFpro.
Complementary DNAs for full-length AML1a, AML1b and ETO coding sequences were PCR amplified from cDNA prepared from CMK total RNA using AML1a (forward: AML1a/F1562-KpnI; reverse: AML1a/R2342-XhoI, 5 0 -TTCA CCTCGAGGGGGAGAGGGATGGACAGAAGAACT-3 0 ), AML1b (forward: AML1a/F1562-KpnI; reverse: AML1c/ R-XhoI) and ETO (forward: ETO/F214-NotI, 5 0 -TTCACGC GGCCGCCCACTTGAAAAACTGAGGTGCTT-3 0 ; reverse: ETO/R2182-NotI, 5 0 -TTCACGCGGCCGCCAATAAGTCA TTACGACCCGTTACTG-3 0 ) primers, respectively. The resulting AML1a and AML1b amplicons were both digested with KpnI and XhoI and cloned into pcDNA3 mammalian expression vector (Invitrogen). The ETO amplicon was digested with NotI and cloned into the NotI site of pcDNA3 vector. Orientations of the pcDNA3-ETO clones were confirmed by DNA sequencing and a sense-oriented clone was chosen for the transfection experiments.
To prepare the full-length coding sequences for the in-frame A1bE and A1cE fusion transcripts and a representative out-offrame A1bE form with intact ETO sequence (3(À156).4.5-( þ 82)-2.3.4//11; Supplementary Table S2), full-length A1E fusion sequences in pCRIITOPO (Invitrogen) were PCR amplified with the AML1b (A1bE/F1552-KpnI)-or AML1c (AML1c/F-KpnI)-specific forward primers (including a KpnI restriction site) and the downstream ETO (A1E/R3863-XhoI) reverse primer (including a XhoI restriction site; see above). The amplicons were digested with KpnI and XhoI, and cloned into KpnI/XhoI-digested pcDNA3. Plasmid DNAs were prepared for automated DNA sequencing to verify the fusion transcripts.
To determine the transcriptional activity of the in-frame A1E fusion proteins, HeLa cells were co-transfected with the pGL3B-GM-CSFpro (1 mg), pRLSV40 (10 ng) and the pcDNA3-A1E fusion constructs (500 ng), using Lipofectamine reagent (Invitrogen) as described by the manufacturer. To determine the effects of the fusion proteins on AML1b transactivation, HeLa cells were co-transfected with 1 mg pGL3B-GM-CSFpro along with 500 ng pcDNA3-AML1b, 500 ng pcDNA3-A1E fusion constructs and 10 ng pRLSV40. Cells were harvested and lysates were prepared 72 h after transfection. Firefly luciferase activities were assayed with a Dual-Luciferase Reporter Assay System (Promega) in a Turner TD2420 luminometer and results were normalized to Renilla luciferase activities.
Western blot analysis
Whole-cell lysates (30 mg total protein) from the transient transfections and from the t(8;21) AML cell line, Kasumi-1, were fractionated on a 10% polyacrylamide gel with SDS and electroblotted onto a polyvinylidene difluoride membrane. AML1 or ETO proteins were detected with an AML1 antibody (3D9; MBL International, Woburn, MA, USA) or an ETO antibody (C-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA), using the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE, USA) as described by the manufacturer.
Statistical analysis
Differences in luciferase activities between groups were compared using a paired t-test. The associations between total A1E or total in-frame A1E and event-free survivals were determined using the nonparametric Spearman rank correlation coefficient. Statistical analyses were performed with GraphPad Prism 4.0.
